Search Results
Targeted therapies for the treatment of mRCC after nivolumab-ipilimumab failure
Frontline Therapy Options for mRCC
Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma
Dr. Pal on the Frontline Approval of Nivolumab and Ipilimumab in mRCC
Nivolumab and ipilimumab for metastatic kidney cancer
Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC
Second-Line Therapy After I/O in mRCC
Cytoreducive Nephrectomy in RCC: Challenges Nurses Face
Managing Advanced Renal Cell Carcinoma - Quinn
Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC
Other Trials and Combinations to Treat Renal Cell Carcinoma
Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC
